Novartis
Bookmark
ShareNovartis is a company. It is in Basel, Switzerland and its CEO is Vasant Narasimhan. It was founded in 1996 and is part of the Health Care sector, specifically in the Pharmaceuticals industry.
Key facts
- city: Basel
- country: Switzerland
- employees: 108,000 people
- revenues: 52.8B $
- sector: Health Care
- industry: Pharmaceuticals
- foundation year: 1996
- CEO: Vasant Narasimhan
- CEO approval: 67 %
- ESG score: Try Pro to see estimate
See more facts
Extract data
Download datasets about Novartis:
Stocks from Novartis:
Novartis is one of the companies in Vasant Narasimhan, companies in Switzerland, companies in Pharmaceuticals, companies in Health Care and 3,584,319 companies in our database.
Talking Points
- Working together, we can reimagine medicine to improve and extend people’s lives.
- Our purpose is to reimagine medicine to improve and extend people’s lives. See our community guidelines: https://t.co/8fvS5jsThu
- Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and ...
- Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
